Rhelion Subsidiary Filament Health Signs Psilocybin Supply Deal for Belgian Compassionate Use Program

• Rhelion Life Sciences' wholly owned subsidiary Filament Health signed a supply and licensing agreement with Belgian psychiatric hospital operator Epsylon.
• Filament will supply its botanical psilocybin drug candidate PEX010 for a compassionate use program targeting treatment-resistant depression.
• The program requires Belgian regulatory approval to provide access outside clinical trials; Rhelion believes it would be Belgium's first such program.
• Epsylon is the program applicant; Filament will provide regulatory support but is not responsible for conducting the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610160855NEWSFILECNPR____20261016_319354_1) on October 16, 2026, and is solely responsible for the information contained therein.